BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics (APGE) to $84 from $81 and keeps a Buy rating on the shares. The company shared “promising” interim data from its Phase 1B study in asthma with zumilokibart and confirmed plans to progress into late-stage development, the analyst tells investors in a research note. The firm currently models $2B in nominal peak sales for Apogee in asthma, with estimated U.S./ex-U.S. launches in 2030/2031.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APGE:
- Apogee Therapeutics: Upgraded Outlook on Zumilokibart’s Superior Asthma Data, Dual-Label Potential, and Strengthened Buy Thesis
- Apogee Therapeutics price target raised to $137 from $128 at BTIG
- Apogee Therapeutics: Differentiated IL-13 Strategy, Durable Efficacy, and 2026 Catalysts Underpin Reaffirmed Buy Rating
- Apogee Therapeutics price target raised to $133 from $95 at Stifel
- Apogee Therapeutics Stock (APGE) Plunges despite ‘Positive’ Asthma Drug Trial